Roche's Perjeta keeps racking up positive news

The positive news keeps rolling in for the Roche ($RHHBY) drug Perjeta, even after it got approved this month by the FDA for HER2-positive disease. The company today said another study found people with HER2-positive metastatic breast cancer lived significantly longer when treated with the combination of Perjeta and its other drug, Herceptin, along with docetaxel chemotherapy, compared with Herceptin and docetaxel chemotherapy alone. Perjeta is a potential blockbuster, with analyst estimates running $600 million to $1 billion-plus. With a couple of additional indications now under study, Perjeta could climb to peak sales of $8.5 billion, Jeffries analysts have said. And it won't cannibalize the standard HER2 treatment Herceptin, because it's designed for use in tandem with the older drug. Release | More